Clinical implementation of routine screening for fetal trisomies in the UK NHS: Cell-free DNA test contingent on results from first-trimester combined test

Ultrasound in Obstetrics and Gynecology

Volumn 47, Issue 1, 2016, Pages 45-52

  Gil, M M ^a   Revello, R ^a   Poon, L C ^a   Akolekar, R ^a,b   Nicolaides, K H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MEDWAY MARITIME HOSPITAL   (United Kingdom)

Author keywords

cell free DNA; fetal trisomy; first trimester combined test

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA; PAPPA1 PROTEIN, HUMAN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; BLOOD; CELL FREE SYSTEM; CHROMOSOME 13; CHROMOSOME 18; CHROMOSOME DISORDERS; COHORT ANALYSIS; DOWN SYNDROME; FEASIBILITY STUDY; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; METABOLISM; NATIONAL HEALTH SERVICE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; PROSPECTIVE STUDY; STATISTICAL MODEL; TRISOMY; UNITED KINGDOM;

ADULT; CELL-FREE SYSTEM; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; COHORT STUDIES; DNA; DOWN SYNDROME; FEASIBILITY STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; STATE MEDICINE; TRISOMY; ULTRASONOGRAPHY, PRENATAL; UNITED KINGDOM;

EID: 84953637496     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.15783     Document Type: Article

References (31)

1. Nicolaides KH,. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
2. Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH,. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther 2014; 35: 118-126.
3. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH,. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015; 45: 249-266.
4. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G,. Noninvasive prenatal testing for fetal trisomies in a routinely screened first trimester population. Am J Obstet Gynecol 2012; 207: 374.e1-e6.
5. Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH,. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013; 42: 34-40.
6. Quezada MS, Gil MM, Francisco C, Oròsz G, Nicolaides KH,. Screening for trisomies 21, 18 and 13 cell-free by DNA analysis of maternal blood at 10-11 weeks' gestation and the combined test at 11-13 weeks. Ultrasound Obstet Gynecol 2015; 45: 36-41.
7. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM,. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013; 42: 41-50.
8. Nicolaides KH, Syngelaki A, Poon LC, Gil MM, Wright D,. First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing. Fetal Diagn Ther 2014; 35: 185-192.
9. Wright D, Wright A, Nicolaides KH,. A unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol 2015; 45: 48-54.
10. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A,. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: 319.e1-9.
11. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH,. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: 322.e1-5.
12. Ashoor G, Syngelaki A, Wang E, Struble C, Oliphant A, Song K, Nicolaides KH,. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol 2013; 41: 21-25.
13. Gil MM, Giunta G, Macalli EA, Poon LC, Nicolaides KH,. UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: factors affecting uptake. Ultrasound Obstet Gynecol 2015; 45: 67-73.
14. Snijders RJM, Sebire NJ, Cuckle H, Nicolaides KH,. Maternal age and gestational age-specific risks for chromosomal defects. Fetal Diagn Ther 1995; 10: 356-367.
15. Wright DE, Bray I,. Estimating birth prevalence of Down's syndrome. J Epidemiol Biostat 2000; 5: 89-97.
16. Office for National Statistics. Live Births in England and Wales by Characteristics of Mother 1, 2013. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-327586 [Accessed 28 September 2015].
17. Cuckle H, Benn P, Pergament E,. Maternal cfDNA screening for Down syndrome - a cost sensitivity analysis. Prenat Diagn 2013; 33: 636-642.
18. Song K, Musci TJ, Caughey AB,. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 2013; 26: 1180-1185.
19. Evans MI, Sonek JD, Hallahan TW, Krantz DA,. Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies. Ultrasound Obstet Gynecol 2015; 45: 74-83.
20. Kuppermann M, Gates E, Washington AE,. Racial-ethnic differences in prenatal diagnostic test use and outcomes: preferences, socieconomics, or patient knowledge? Obstet Gynecol 1996; 87: 675-682.
21. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, Craig JA, Chudova DI, Devers PL, Jones KW, Oliver K, Rava RP, Sehnert AJ,; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014; 370: 799-808.
22. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Hollemon D, Cuckle H, Musci TJ, Wapner RJ,. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015; 372: 1589-1597.
23. Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J,. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 2013; 33: 700-706.
24. Alberman E, Huttly W, Hennessy E, McIntosh A,. The use of record linkage for auditing the uptake and outcome of prenatal serum screening and prenatal diagnostic tests for Down syndrome. Prenat Diagn 2003; 23: 801-806.
25. Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A,. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol 2005; 193: 322-326.
26. Mueller VM, Huang T, Summers AM, Winsor SH,. The influence of risk estimates obtained from maternal serum screening on amniocentesis rates. Prenat Diagn 2005; 25: 1253-1257.
27. Benn PA, Fang M, Egan JF,. Trends in the use of second trimester maternal serum screening from 1991 to 2003. Genet Med 2005; 7: 328-331.
28. Jaques AM, Collins VR, Muggli EE, Amor DJ, Francis I, Sheffield LJ, Halliday JL,. Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome. Prenat Diagn 2010; 30: 522-530.
29. Lichtenbelt KD, Schuring-Blom GH, van der Burg N, Page-Christiaens GC, Knoers NV, Schielen PC, Koster MP,. Factors determining uptake of invasive testing following first-trimester combined testing. Prenat Diagn 2013; 33: 328-333.
30. Chetty S, Garbedian MJ, Norton ME,. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013; 33: 542-546.
31. Natoli JL, Ackerman DL, McDermott S, Edwards JG,. Prenatal diagnosis of Down syndrome: a systematic review of termination rates (1995-2011). Prenat Diagn 2012; 32: 142-153.